Start with the question
Connect the research goal to the antigen, HLA context and experimental endpoint.
A focused platform CRO built on renewable eDC technology.
Our mission
CrossRelay was built by the scientists who invented eDC technology. It gives immunotherapy researchers a renewable APC system and the functional data needed to interpret it.
Our APC drug discovery platform supports scientists and biotech laboratories studying immune mechanisms, validating antigen-related responses and investigating drug targets. We bring together antigen-expressing eDC lines, paired cellular assay systems, cytokines for culture and custom development from customer PBMCs. The platform also supports target nomination for antibody-directed programs and the screening of immunomodulatory biologics.
Connect the research goal to the antigen, HLA context and experimental endpoint.
Present data with the tested configuration, controls and context needed for interpretation.
Define the requested eDC configuration, engineering scope and scientific deliverables together.
The inventors of eDC technology form the scientific foundation of CrossRelay.
CrossRelay turns the inventors’ experience with eDC technology into products and project support for APC drug discovery. Each project is built around a defined antigen, a relevant HLA context and a functional question.
Wu L, Zhang H, Jiang Y, Gallo RC, Cheng H. 115(19):E4453–E4462. DOI: 10.1073/pnas.1800550115.
View publicationZhao C et al. 74:117. DOI: 10.1007/s00262-025-03971-y.
View publicationSelected publications provide scientific context. Consult the documentation for the specific eDC configuration when assessing product suitability.